semaglutide adverse events Diabetes Distilled: Greater reductions in HbA1c ACHIEVEd with orforglipron versus oral 14 mg A Placebo-Controlled Trial of Subcutaneous

We take time to listen, educate, and partner with every patient

Choose a consistent time each day, before eating anything

Retatrutide is part of a new class of medications known as multi-agonist peptides, designed to target multiple pathways involved in appetite regulation and metabolism

Safety in TRIUMPH-1 The safety profile was consistent with incretin-class therapies: Most common AEs (12 mg dose): - Nausea: 42.4% - Diarrhea: 32.0% - Constipation: 26.1% - Vomiting: 25.3% Dysesthesia (a sensory disturbance tingling, numbness) and urinary tract infections were reported in approximately 10% of patients on the highest doses, but were generally mild to moderate and mostly resolved during treatment

Research Square PrintOctober 14th, 2022